Disappointment & Surprise But Not Giving Up: Companies Respond To English Funding Rejection For COVID-19 Treatments
Executive Summary
MSD, Gilead, GSK, AstraZeneca and Roche told the Pink Sheet what they thought of draft guidance that the health technology assessment institute, NICE, published today, recommending against routine commissioning for five COVID-19 treatments.
You may also be interested in...
AstraZeneca's Evusheld Revenue Stream To Dry Up Soon
The revenue boost Evusheld has given AstraZeneca over the past year will grind to a halt now that the FDA, as expected, has pulled approval for the antibody combo on the grounds it is ineffective against most SARS-CoV-2 variants circulating in the US.
England OKs Routine Funding For Three COVID-19 Treatments But Rejects Five Others
The clinical and cost-effectiveness of Paxlovid, RoActemra, Olumiant, Ronapreve, Lagevrio, Veklury, Xevudy and Evusheld are discussed in a draft guidance from England’s health technology assessment institute, which says it is ready to work with the companies whose products it has not recommended.
England OKs Routine Funding For Three COVID-19 Treatments But Rejects Five Others
The clinical and cost-effectiveness of Paxlovid, RoActemra, Olumiant, Ronapreve, Lagevrio, Veklury, Xevudy and Evusheld are discussed in a draft guidance from England’s health technology assessment institute, which says it is ready to work with the companies whose products it has not recommended.